|
|
|
|
Dosage changes in patients with long-term botulinum toxin use for laryngeal dystonia
dystonia Email Password Remember me HomeGeneral Topics in D Scott Cunningham MD, PhD, MDLinx Article Summary Click the title below to leave the MDLinx Network and go to the Journal's Website Otolaryngology , 01/09/09 Save in Birkent H...
|
|
|
FDA Issues Complete Response Letter to Ipsen for Dysport Biologics License Application
- (NewsRx.com) -- Regulatory News: No additional clinical data requested Manufacturing process for Dysport in compliance with CGMPs1No Form 483 observation listed FDA requests finalization of the Risk Evaluation and Mitigation Strategy and...
|
|
|
Ipsen: FDA's First-Cycle Review Of Reloxin(R) Extended
Ipsen (Paris:IPN) announced that the U.S.Food and Drug Administration (FDA) provided notification that the Prescription Drug User Fee Act (PDUFA) action date for Reloxin (botulinum toxin of type A) Biologics License Application (BLA) in...
|
|
|
Ipsen: FDAEURs First-Cycle Review of Reloxin(R) Extended
PARIS--(BUSINESS WIRE)--Regulatory News:Ipsen (Paris:IPN) today announced that the U.S.Food and Drug Administration (FDA) provided notification that the Prescription Drug User Fee Act (PDUFA) action date for Reloxin (botulinum toxin of...
|
|
|
Intraventricular baclofen for dystonia: techniques and outcomes
Albright AL et al.- Intraventricular baclofen is an effective method of infusing baclofen to treat severe, generalized secondary dystonia, and, at times, heredodegenerative dystonia. The site of baclofen's activity when...
|
|
|
Ipsen: FDA's First-Cycle Review of Reloxin Extended
Ipsen (Paris:IPN) today announced that the U.S.Food and Drug Administration (FDA) provided notification that the Prescription Drug User Fee Act (PDUFA) action date for Reloxin (botulinum toxin of type A) Biologics License Application (BLA...
|
|
|
Ipsen: FDAEURs First-Cycle Review of Reloxin Extended
Regulatory News: Ipsen (Paris:IPN) today announced that the U.S.Food and Drug Administration (FDA) provided notification that the Prescription Drug User Fee Act (PDUFA) action date for Reloxin (botulinum toxin of type A) Biologics License...
|
|
|
FDA Issues Complete Response Letter To Ipsen For Dysport Biologics License Application For Treatment Of Cervi
Ipsen (Paris:IPN) today announced that the US Food and Drug Administration (FDA) issued a Complete Response Letter for its Biologics License Application (BLA) for its Botulinum toxin Type A, Dysport.The application, submitted by the Group...
|
|
|
Ipsen receives FDA complete response letter for Dysport's BLA
The application, submitted previously by the group in late 2007, seeks approval to market Dysport for the treatment of cervical dystonia.The group said that it is now actively preparing to launch the product, once approved by the...
|
|
|
FDA issues complete response letter to Ipsen for Dysport BLA
Ipsen has announced that the US Food and Drug Administration (FDA) issued a Complete Response Letter for its Biologics License Application (BLA) for its Botulinum toxin Type A, Dysport.The application, submitted by the Group in late 2007,...
|
|
|
US FDA issues complete response letter to Ipsen for Dysport BLA
Ipsen announced that the US Food and Drug Administration (FDA) issued a Complete Response Letter for its Biologics License Application (BLA) for its Botulinum toxin type-A, Dysport.The application, submitted by the group in late 2007,...
|
|
|
Ipsen receives FDA complete response letter for Dysport's BLA
France-based pharmaceutical company Ipsen has announced that the FDA has issued a complete response letter for its biologics license application for its botulinum toxin type A, Dysport.The application, submitted previously by the group in...
|
|
|
Ipsen eyes U.S. Dysport launch clearance in mid-2009
* FDA issues complete response letter to Ipsen for Dysport Biologics License Application * Says no additional clinical data requested * Sees submiting the information to FDA during the first quarter of 2009 PARIS (Reuters) - French drugmaker...
|
|
|
Ipsen Release: FDA Issues Complete Response Letter to Ipsen for Dysport(R) Biologics License Application
PARIS--(BUSINESS WIRE)--Regulatory News: Ipsen (Paris:IPN) today announced that the US Food and Drug Administration (FDA) issued a Complete Response Letter for its Biologics License Application (BLA) for its Botulinum toxin Type A, Dysport....
|
|
|
FDA Issues Complete Response Letter to Ipsen for Dysport Biologics License Application
Manufacturing process for Dysport in compliance with CGMPs1 No Form 483 observation listed FDA requests finalization of the Risk Evaluation and Mitigation Strategy and labelling Stepping-up to Dysport's full launch preparation phase PARIS--...
|
|
|
FDA Issues Complete Response Letter to Ipsen for Dysport Biologics License Application
No additional clinical data requested Manufacturing process for Dysport in compliance with CGMPs1 No Form 483 observation listed FDA requests finalization of the Risk Evaluation and Mitigation Strategy and labelling Stepping-up to Dysport's...
|
|
|
Relief By Botulinum Toxin Of Lower Urinary Tract Symptoms Owing To Benign Prostatic Hyperplasia: Early And Lon
UroToday.com - Botulinum toxin (BTX) is used therapeutically for several disorders associated with excessive muscular contractions including focal dystonias.Recently BTX has been successfully used for the treatment of disorders of...
|
|
|
The Main Cause Of Abnormal Muscle Constrictions In Dystonia Is Decreased Activity Of Basal Ganglia
Neurology / Neuroscience News Main Category: Neurology / Neuroscience Also Included In: Biology / Biochemistry email to a friend printer friendly view / write opinions rate article Current Article Ratings: Patient / Public: Health...
|
|
|
Cause found for abnormal muscle constrictions in dystonia
Medical Condition News Dystonia is a neurological disorder characterized by involuntary abnormal muscle constrictions.More than 300,000 people in North America are affected, but the mechanism of abnormal muscle constrictions has not...
|
|
|
Decreased activity of basal ganglia is the main cause of abnormal muscle constrictions in dystonia
Dystonia is a neurological disorder characterized by involuntary abnormal muscle constrictions.More than 300,000 people in North America are affected, but the mechanism of abnormal muscle constrictions has not been well understood....
|
|
|
Gene Therapy - Scientists at Emory University, Medical Department discuss research in gene therapy
'Hypertonia, which is characterized by stiff gait, abnormal posture, jerky movements, and tremor, is associated with a number of neurological disorders, including cerebral palsy, dystonia, , stroke, and injury.Recently, a...
|
|
|
Scientists at Emory University, Medical Department discuss research in gene therapy
- (NewsRx.com) -- 'Hypertonia, which is characterized by stiff gait, abnormal posture, jerky movements, and tremor, is associated with a number of neurological disorders, including cerebral palsy, dystonia, Parkinson's disease, stroke,...
|
|
|
Novel Techniques Offers New Freedom to Patients with Parkinson's Disease, Epilepsy, Dystonia, and Tremor
Brian Snyder, a neurosurgeon at Neurological Surgery PC of Long Island, NY, describes how state-of-the-art treatments in which he is specially trained can help relieve some of the symptoms caused by neurological diseases.is a practice...
|
|
|
Novel Techniques Offers New Freedom to Patients with Parkinson's Disease, Epilepsy, Dystonia, and Tremor
Neurological Surgery, PC, welcomes Dr.Brian J. Snyder to the practice. Snyder is one of the very few neurosurgeons on Long Island trained to perform the procedures which are described below. D Neurological Surgery, PC - Long Island,...
|
|
|
Proteins within the type E botulinum neurotoxin complex
Title: United States Patent: 7,431,935 Inventors: Singh; Bal Ram (Dartmouth, MA), Zhang; Zhong (New Bedford, MA) Assignee: University of Massachusetts (Boston, MA) Appl.No.: 10/766,283 Filed: January 27, 2004 The invention features a...
|
